GLP-2 Conjugate Pharmaceutical Composition for Metabolic Bone Diseases, Hanmi Pharm.
Summary
The European Patent Office published application EP4082561A1 for Hanmi Pharm. Co., Ltd. on April 15, 2026. The application covers a pharmaceutical composition comprising GLP-2 or a conjugate thereof for preventing or treating metabolic bone diseases, with inventors including CHOI Jae Hyuk, LEE Jin Bong, LEE Sang Hyun, LEE Sang Don, and KIM Min Young. The application spans 31 designated contracting states including major European economies.
About this source
GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 22 changes logged to date.
What changed
The EPO published patent application EP4082561A1, filed by Hanmi Pharm. Co., Ltd., covering pharmaceutical compositions containing GLP-2 or conjugates thereof for preventing or treating metabolic bone diseases. The application was published on April 15, 2026, with inventors CHOI Jae Hyuk, LEE Jin Bong, LEE Sang Hyun, LEE Sang Don, and KIM Min Young.
Affected parties include pharmaceutical companies developing GLP-2 based therapies for bone disorders who may need to review freedom-to-operate considerations in European markets. Competitors in the metabolic bone disease treatment space should monitor this application given Hanmi's entry into this therapeutic area. The publication provides public notice of the claimed invention, initiating the 18-month opposition window following grant.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC BONE DISEASES, COMPRISING GLP-2 OR CONJUGATE THEREOF
Publication EP4082561A1 Kind: A1 Apr 15, 2026
Applicants
Hanmi Pharm. Co., Ltd.
Inventors
CHOI, Jae Hyuk, LEE, Jin Bong, LEE, Sang Hyun, LEE, Sang Don, KIM, Min Young
IPC Classifications
A61K 38/26 20060101AFI20240102BHEP A61K 47/60 20170101ALI20240102BHEP A61K 47/68 20170101ALI20240102BHEP A61P 19/10 20060101ALI20240102BHEP A61P 19/02 20060101ALI20240102BHEP C07K 14/605 20060101ALI20240102BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.